Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor.
Adult
Angiotensin II Type 1 Receptor Blockers
/ administration & dosage
Benzhydryl Compounds
/ administration & dosage
Canagliflozin
/ administration & dosage
Diabetic Nephropathies
/ classification
Drug Therapy, Combination
/ methods
Female
Glomerular Filtration Rate
/ drug effects
Glucagon-Like Peptide-1 Receptor
/ administration & dosage
Glucosides
/ administration & dosage
Humans
Imidazoles
/ administration & dosage
Irbesartan
/ administration & dosage
Liraglutide
/ administration & dosage
Male
Middle Aged
Proteinuria
/ drug therapy
Sodium-Glucose Transporter 2 Inhibitors
/ administration & dosage
Tetrazoles
/ administration & dosage
Treatment Outcome
Angiotensin II receptor blocker
Glucagon-like peptide-1 receptor agonist
Rapidly progressive diabetic nephropathy
Sodium glucose transporter-2 inhibitor
Journal
CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
03
12
2018
accepted:
11
01
2019
pubmed:
22
1
2019
medline:
19
3
2020
entrez:
22
1
2019
Statut:
ppublish
Résumé
We herein report two cases of advanced stage rapidly progressive diabetic nephropathy that were effectively treated with combination therapy including renin-angiotensin-aldosterone system (RAS) blocker [angiotensin II receptor blocker (ARB)], glucagon-like peptide-1 (GLP-1) receptor agonist and sodium glucose transporter-2 (SGLT-2) inhibitor. A 30-year-old woman with advanced stage diabetic nephropathy [estimated glomerular filtration rate (eGFR): 20.7 mL/min/1.73 m
Identifiants
pubmed: 30663011
doi: 10.1007/s13730-019-00379-3
pii: 10.1007/s13730-019-00379-3
pmc: PMC6450986
doi:
Substances chimiques
Angiotensin II Type 1 Receptor Blockers
0
Benzhydryl Compounds
0
Glucagon-Like Peptide-1 Receptor
0
Glucosides
0
Imidazoles
0
Sodium-Glucose Transporter 2 Inhibitors
0
Tetrazoles
0
Canagliflozin
0SAC974Z85
Liraglutide
839I73S42A
olmesartan
8W1IQP3U10
Irbesartan
J0E2756Z7N
6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol
P8DD8KX4O4
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
128-133Références
Curr Opin Nephrol Hypertens. 2001 Jan;10(1):105-10
pubmed: 11195042
Lancet. 2015 May 23;385(9982):2047-56
pubmed: 26009228
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Diabetologia. 2011 Apr;54(4):965-78
pubmed: 21253697
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704
pubmed: 29937267
Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617
pubmed: 29910024
Horm Metab Res. 2016 Mar;48(3):191-5
pubmed: 26158396
Diabetes Ther. 2018 Apr;9(2):637-650
pubmed: 29460259
Lancet Diabetes Endocrinol. 2014 May;2(5):369-84
pubmed: 24795251
Tohoku J Exp Med. 2013;231(1):57-61
pubmed: 24064677
Nat Rev Nephrol. 2016 Nov 16;12(12):711-712
pubmed: 27847389
J Clin Invest. 1986 Jun;77(6):1925-30
pubmed: 3011862
Circulation. 2014 Feb 4;129(5):587-97
pubmed: 24334175